PAVmed (NASDAQ:PAVM – Get Free Report) and Envoy Medical (NASDAQ:COCH – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.
Institutional and Insider Ownership
19.9% of PAVmed shares are held by institutional investors. Comparatively, 8.6% of Envoy Medical shares are held by institutional investors. 13.4% of PAVmed shares are held by company insiders. Comparatively, 7.2% of Envoy Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Risk and Volatility
PAVmed has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500. Comparatively, Envoy Medical has a beta of 1.91, meaning that its stock price is 91% more volatile than the S&P 500.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| PAVmed | -10,794.64% | -126.43% | -25.49% |
| Envoy Medical | -11,304.83% | N/A | -144.13% |
Earnings & Valuation
This table compares PAVmed and Envoy Medical”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| PAVmed | $70,000.00 | 556.00 | $400,000.00 | ($16.05) | -0.30 |
| Envoy Medical | $240,000.00 | 228.68 | -$23.76 million | ($0.76) | -0.94 |
PAVmed has higher earnings, but lower revenue than Envoy Medical. Envoy Medical is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent ratings for PAVmed and Envoy Medical, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| PAVmed | 1 | 1 | 1 | 0 | 2.00 |
| Envoy Medical | 1 | 1 | 1 | 0 | 2.00 |
PAVmed currently has a consensus price target of $56.00, indicating a potential upside of 1,051.08%. Envoy Medical has a consensus price target of $2.00, indicating a potential upside of 181.29%. Given PAVmed’s higher probable upside, equities research analysts plainly believe PAVmed is more favorable than Envoy Medical.
Summary
PAVmed beats Envoy Medical on 8 of the 12 factors compared between the two stocks.
About PAVmed
PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
About Envoy Medical
Envoy Medical, Inc., a hearing health company, provides medical technologies for the hearing loss spectrum. Its products include personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc. in September 2023. Envoy Medical, Inc. was founded in 1995 and is headquartered in White Bear Lake, Minnesota.
Receive News & Ratings for PAVmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed and related companies with MarketBeat.com's FREE daily email newsletter.
